Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Avoid URU Metals Ltd. (DI) (URU) by Nigel Somerville in ShareProphets
- Sell Videndum (VID) by Steve Moore in ShareProphets
- Avoid PZ Cussons (PZC) by Steve Moore in ShareProphets
- Avoid TT Electronics (TTG) by Steve Moore in ShareProphets
- Sell Microsaic Systems (MSYS) by Steve Moore in ShareProphets
- Sell The Revel Collective (TRC) by Steve Moore in ShareProphets
- Buy KEFI Gold and Copper (KEFI) by Hot Stock Rockets in ShareProphets
- Avoid Naked Wines (WINE) by Steve Moore in ShareProphets
- Sell Mirriad Advertising (MIRI) by Steve Moore in ShareProphets
- Hold M&G (MNG) by Cliff D'Arcy in The Motley Fool
- Buy Safestore Holdings (SAFE) by Zaven Boyrazian in The Motley Fool
- Buy Altona Rare Earths (REE) by Hot Stock Rockets in ShareProphets
- Avoid Surgical Innovations Group (SUN) by Steve Moore in ShareProphets
- Outperform OSB Group (OSB) by RBC Capital
- Buy Diageo (DGE) by Harvey Jones in The Motley Fool
- Watch Nexteq (NXQ) by Steve Moore in ShareProphets
- Overweight Jet2 (JET2) by Barclays
- Outperform IntegraFin Holding (IHP) by RBC Capital
- Outperform Volution Group (FAN) by RBC Capital
- Sector Perform Currys (CURY) by RBC Capital
Shield Therapeutics (STX) Share Price
Health Care Sector
NOTE: This is based on 61 open tips for Shield Therapeutics (STX)
| Latest Bid : 10.50p | Latest Ask : 11.00p |
| High Today : 11.25p | Low Today : 10.50p |
| This Years High : 11.80p | This Years Low : 2.25p |
| Volume : 929,840 | MKT Cap : £86.02M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Shield Therapeutics (STX) Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.Shield Therapeutics (STX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Peel Hunt | Premium Only | 2025-11-07 16:31:00 07/11/2025 | 53.28% |
| Buy | Peel Hunt | Premium Only | 2025-09-15 11:19:00 15/09/2025 | 28.05% |
| Sell | Tom Winnifrith | Premium Only | 2024-02-21 12:20:00 21/02/2024 | -279.31% |
| Buy | William Kay | Premium Only | 2023-09-29 00:05:00 29/09/2023 | 37.25% |
| Buy | Peel Hunt | Premium Only | 2023-02-09 09:31:00 09/02/2023 | 47.89% |
Shield Therapeutics (STX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 10.50p | Latest Ask : 11.00p |
| High Today : 11.25p | Low Today : 10.50p |
| This Years High : 11.80p | This Years Low : 2.25p |
| Volume : 929,840 | MKT Cap : £86.02M |
Shield Therapeutics Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Shield Therapeutics Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Peel Hunt | Premium Only | 2025-11-07 16:31:00 07/11/2025 | 53.28% |
| Buy | Peel Hunt | Premium Only | 2025-09-15 11:19:00 15/09/2025 | 28.05% |
| Sell | Tom Winnifrith | Premium Only | 2024-02-21 12:20:00 21/02/2024 | -279.31% |
| Buy | William Kay | Premium Only | 2023-09-29 00:05:00 29/09/2023 | 37.25% |
| Buy | Peel Hunt | Premium Only | 2023-02-09 09:31:00 09/02/2023 | 47.89% |